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Introduction: Nuclear expression of Y-box binding protein-1
(YB-1) is closely associated not only with global drug resistance and
expression of several growth factor receptors in various human
malignancies but also with overall patient survival.
Methods: The effect of YB-1 knockdown on expression of epider-
mal growth factor receptor (EGFR) family proteins was examined
by Western blot using human lung cancer cell lines. Immunohisto-
chemistry was used to evaluate the expression of nuclear YB-1 and
EGFR family proteins in patients with non-small cell lung cancer
(NSCLC) (n  104).
Results: In the five NSCLC cell lines, expressions of EGFR, human
epidermal growth factor receptor 2 (HER2), HER3, and hepatocyte
growth factor receptor (c-Met) in PC-9 cells; of HER2 and c-Met in
EBC-1 cells; and of HER3 in QG56 cells were down-regulated by
YB-1 knockdown. By immunohistochemical analysis, we observed
that HER3 expression was significantly negatively correlated with
nuclear YB-1 expression in squamous cell carcinoma (p  0.038).
HER2 expression was positively correlated with nuclear YB-1
expression in adenocarcinoma (p  0.052). Nuclear expression of
YB-1 correlated with overall survival of all patients (p 0.028) and
of patients with adenocarcinoma (p  0.007). Furthermore, there
was a significant difference in therapeutic efficacies of gefitinib
between patients with nuclear YB-1 expression and those with
non-nuclear YB-1 expression in patients with NSCLC (p  0.004,
n  26) but not between those with high and those with low
expression of EGFR, HER2, HER3, and c-Met.
Conclusion: Nuclear YB-1 expression might be essential for the
malignant phenotype in lung cancer patients and might be an
important biomarker for the development of therapeutic strategy
against NSCLC.
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The Y-box binding protein-1 (YB-1), whose cold shockdomain is highly conserved, plays essential roles in DNA
damage repair and in both transcriptional and translational
regulation of various genes in nucleus and cytoplasm.1,2 In
the nucleus, YB-1 recognizes DNA damage induced by
cisplatin and radiation and promotes transcription of drug-
resistance relevant genes such as MDR1/ABCB1, a representa-
tive multidrug resistance-related ATP-binding cassette trans-
porter, and major vault protein/lung resistance-related protein, a
drug-resistance-related vault protein, suggesting the applicability
of YB-1 as a global biomarker of drug resistance.2,3 Moreover,
nuclear expression of YB-1 significantly correlates with the
survival of patients with various malignancies, including ovarian
cancer,4,5 synovial sarcoma and rhabdomyosarcoma,6,7 lung
cancer,8 breast cancer,9 and pediatric glioblastoma.10 Most of
these patients show a close association of nuclear YB-1 expres-
sion with poor prognosis, irrespective of treatment modality. It is
likely that multiple tumor characteristics, including growth and
metastasis/invasion as well as acquisition of global drug resis-
tance, cause YB-1 expression to be associated with poor prog-
nosis in cancer patients.
Nuclear expression of YB-1 is promoted through PI3K/
Akt signaling in human breast and ovarian cancer cells in
response to growth stimulation,11,12 and YB-1 knockdown
suppresses expression of DNA replication-related and
growth/cell cycle-related genes as well as growth factor
genes.12,13 YB-1 gene knock-in promotes development of
breast cancer of various histologic types in animal models,
suggesting that YB-1 is a breast cancer oncogene.14 YB-1
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knockdown in mice causes embryonic lethality and severe
growth retardation.15,16 Furthermore, YB-1 overexpression
induces epidermal growth factor (EGF)-independent growth
through constitutive EGF receptor (EGFR) activation in hu-
man mammary cells in vitro.17 Wu et al.18 reported that the
introduction of an Akt-activation-insensitive mutation into
YB-1 caused a marked decrease in the expression of both
EGFR and human epidermal growth factor receptor 2
(HER2), suggesting a close linkage between YB-1 and ex-
pression of EGFR and HER2 in breast cancer cells in vitro.
YB-1 knockdown also results in markedly decreased expres-
sion of EGFR and HER2 in some human breast cancer cell
lines in culture.9 Taken together, these basic studies in vitro
and in vivo strongly suggest that YB-1 is closely involved in
EGF/transforming growth factor--dependent and -indepen-
dent tumor growth and carcinogenesis in cancer.
The clinical study by Janz et al.19 was the first to
demonstrate the close association of nuclear YB-1 expression
with HER2 expression in primary breast cancers. This corre-
lation with the expression of EGFR and HER2 in patients
with breast cancer (n  389) was further supported by array
studies with tumor tissue.18 Of various genes, including
EGFR, HER2, ER, ER, and CXCR4, that could be affected
by YB-1 knockdown in vitro, biostatistical analysis showed that
YB-1 nuclear expression was positively associated with the
expression of HER2 and negatively associated with the expres-
sion of CXCR4 and ER.9 A recent study by Stratford et al.20
also showed the possible involvement of YB-1 in the therapeutic
efficacy of an EGFR-targeting drug, gefitinib, in basal-like
breast cancer. These findings suggest that YB-1 may play a key
role in the expression of cell growth-related genes, including
EGFR family genes, in breast cancer cells and may also mod-
ulate the therapeutic efficacy of EGFR family targeting drugs.
In this study, we determined the relationship between
YB-1 expression and that of several growth factor receptors,
EGFR, HER2, HER3, hepatocyte growth factor receptor
(c-Met), and insulin-like growth factor 1 receptor (IGF-1R), in
human lung cancer cell lines in culture. Moreover, we deter-
mined whether nuclear YB-1 expression was correlated with the
expression of EGFR, HER2, HER3, c-Met, and phosho Akt
(pAkt) in tumor tissue from patients with non-small cell lung
cancer (NSCLC), and also whether therapeutic efficacy of ge-
fitinib was correlated with nuclear YB-1 expression. We discuss
the clinical and immunohistochemical characteristics of NSCLC
with particular reference to the absence or presence of nuclear
YB-1 expression and the expression of EGFR family proteins.
MATERIALS AND METHODS
Cell Lines and Reagents
PC-9, QG56, and 11_18 were cultured in Roswell Park
Memorial Institute (culture medium) supplemented with 10%
fetal bovine serum. A549 and EBC-1 were cultured in Dulbec-
co’s minimum essential medium supplemented with 10% fetal
bovine serum. Anti-YB-1 was generated as described previous-
ly.21 Anti-EGFR, IGF-1R, Akt, pAkt, Erk, and pErk antibodies
were obtained from Cell Signaling Technology (Beverly, MA).
Anti-HER2 was purchased from Upstate, Inc. (Lake Placid,
NY). Antic-Met and anti-HER3 were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Anti-GAPDH was pur-
chased from TREVIGEN (Gaithersburg, MD).
Small Interfering RNA Transfection and
Immunoblotting
The small interfering RNA (siRNA) corresponding to the
nucleotide sequence of YB-1 was purchased from QIAGEN.9
SiRNA duplexes were transfected with Lipofectamine
RNAiMAX and Opti-MEMmedium (Invitrogen, Carlsbad, CA)
according to the manufacturer’s recommendations. Forty-eight
hours after siRNA transfection, cells were lysed in cold protein
extraction reagent (M-PER; PIERCE, Rockford, IL) with pro-
tease inhibitors and phosphatase inhibitors. Nuclear and cyto-
plasmic fractions were prepared as described previously.12
Lysates were subjected to SDS-PAGE and blotted onto Immo-
bilon membrane (Millipore Corp., Bedford, MA). After transfer,
the membrane was incubated with the primary antibody and
visualized with secondary antibody coupled to horseradish per-
oxidase and enhanced chemiluminescence Western Blotting
Detection Reagents (GE Healthcare, Piscataway, NJ). For cell
proliferation assay, 2.5 104 cells were seeded in 24-well plates
(IWAKI, Tokyo, Japan) and cell number in each well was
counted at 96 hours after transfection of siRNA.
Patients and Tumor Samples
We examined 104 patients with primary NSCLC whose
tumors had been completely surgically removed in the De-
partment of Surgery of Kurume University between 1997 and
2004. Among the 104 patients, 66 patients were diagnosed
histologically as having adenocarcinoma and the other 38
patients were diagnosed as having squamous cell carcinoma.
The age of the patients with NSCLC ranged from 41 to 82
years (median, 66 years). Of the total number of patients, 67
were men and 37 were women. The median follow-up was
1511.5 days with a range of 159 to 3801 days. Of these
patients, 26 patients received gefitinib against recurrent dis-
ease after surgical resection between June 2003 and Septem-
ber 2008 with the median interval between operation and
gefitinib treatment of 760 days (range, 225-3062 days). Five
patients were treated with gefitinib as an initial therapy and
the others were treated with gefitinib as a second- or a
third-line therapy (21 patients, platinum doublets as first line;
five patients, monotherapy, nonplatinum doublets, and plati-
num doublets as second line).
Immunohistochemistry
Paraffin-embedded tissue samples were cut at 4 m,
placed on coated glass slides, and labeled with the following
antibodies by the BenchMark XT (Ventana Automated Systems,
Inc., Tucson, AZ) or ChemMate ENVISION (DakoCytomation,
Glostrup, Denmark) methods: YB-1, EGFR, HER2, HER3,
pAkt, and c-Met. The BenchMark XT method was used for
YB-1, EGFR, HER2, and HER3. This automated system used
the streptavidin biotin complex method with DAB as chromogen
(Ventana iVIEW DAB Detection Kit). Antigen retrieval of
YB-1 and HER2 was performed by heat treatment in CC1
(Ventana, Inc.) and that of EGFR and HER3 was performed by
protease treatment (protease K, Ventana, Inc.). The ChemMate
ENVISION method was used for pAkt and c-Met. Endogenous
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peroxidase activity was inhibited by incubating the slides in 3%
H2O2 for 5 minutes. Each slide was incubated overnight with the
antibody at 4°C. For staining detection, DAB was used as
chromogen. The samples were viewed using an Olympus BX51
microscope (Olympus, Tokyo, Japan).
Expression of YB-1 protein with variable intensity
showed in the nuclei and/or cytoplasm with variable inten-
sity. Only nuclei of cancer cells with strong expression were
interpreted as positive. Expression of EGFR and HER2 was
classified into four categories: score 0, no staining at all or
weak membrane expression in 10% of cancer cells; score
1, weak expression in 10% of cancer cells; score 2,
weak to moderate expression on the entire membrane in
10% of the cancer cells; and score 3, strong expression on
the entire membrane in 10% of cancer cells. HER3, pAkt,
and c-Met were classified into the same four categories but
the localization of expression included both membrane and
cytoplasm. The scoring of immunohistochemistry (IHC) was
defined as follows in order that the difference in the number
of patients in two categories of negative and positive were as
small as possible. The expressions of HER2 and pAkt were
defined as follows: scores of 2 or 3 were regarded as
positive and scores of 0 or 1were regarded as negative. The
expression of IHC for EGFR, HER3, and c-Met was defined
as follows: score of 3 was regarded as positive and scores
of 0, 1, or 2 were regarded as negative. All IHC studies
were evaluated by two IHC-experienced reviewers (A.K. and
M.K.) who were blinded to the clinical status of the patients.
Statistical Analysis
Associations between histologic type and clinicopath-
ologic findings (age, gender, smoking status, stage, and his-
tologic differentiation) and molecular markers (EGFR,
HER2, HER3, c-Met, and pAkt) were tested by Fisher’s exact
test. Associations between YB-1 and clinicopathologic find-
ings and other molecular markers were tested in similar ways.
A p value 0.05 was regarded as statistically significant
unless indicated. The overall survival was defined as time to
death because of any case from the date of surgical operation.
The relationships between overall survival and YB-1 expres-
sion, and other clinicopathologic findings and molecular
markers, were examined by the Kaplan-Meier method and the
log-rank test. Hazard ratios (HRs) were estimated by Cox
regressions. Adjusted HRs for possible confounding factors
were also estimated by applying the Cox regression models
with the factors as explanatory variables. Twenty-six patients
were treated with gefitinib after progressive disease. Time to
further progressive disease from initiation of gefitinib treat-
ment was evaluated for these patients. The effect of YB-1 on
the further progressive disease in the presence of gefitinib
was examined in an exploratory matter by the Kaplan-Meier
method and the log-rank test. Statistical analysis was per-
formed with SAS version 9.1 (SAS Institute, Inc., Cary, NC)
and revised version 2.7.0.
RESULTS
Knockdown of YB-1 and Expression of the
EGFR, HER2, HER3, and c-Met Genes in NSCLC
Cell Lines
We examined expression of the growth factor receptors
EGFR, HER2, HER3, c-Met, and IGF-1R in five NSCLC cell
lines. Expression of YB-1 was observed in both total cell
fraction and nucleus in all the five NSCLC cell lines, al-
though expression of YB-1 in both fractions of PC-9 and
EBC-1 cells was only about 20% or less than that in the other


















































































FIGURE 1. Expression of YB-1,
EGFR, HER2, HER3, c-Met, and
IGF-1R in human lung cancer cells.
A, Expression of total and nuclear
YB-1, EGFR, HER2, HER3, c-Met, and
IGF-1R was determined by immuno-
blotting conducted on protein ly-
sates extracted from these cell lines.
Detection of GAPDH served as a
loading control. B, Levels of total
and nuclear YB-1, EGFR, HER2,
HER3, c-Met, and IGF-1R expression
were measured by densitometry.
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HER2, HER3, c-Met, and IGF-1R varied among the five cell
lines. Among the various cell lines, the two lines (PC-9 and
EBC-1) with relatively low levels of YB-1 in the nucleus
contained much lower amounts of IGF-1R protein than did
the other three lines. However, expression of the other recep-
tors (EGFR, HER2, HER3, and c-Met) was not significantly
associated with expression levels of YB-1 in nucleus or total
cell fraction of any of the cell lines. We next compared
protein expression levels in the five NSCLC cell lines after
treatment with YB-1 siRNA (Figure 2). Western blot analysis
showed that YB-1 siRNA decreased protein levels of YB-1 in
all five NSCLC cell lines. YB-1 knockdown resulted in
decreased expression of EGFR in PC-9, of HER2 in PC-9 and
EBC-1, of HER3 in PC-9 and QG56, and of c-Met in PC-9
FIGURE 2. Effect of YB-1 knockdown on expression of EGFR, HER2, HER3, c-Met, and IGF-1R in human lung cancer cells. A,
Effect of YB-1 knockdown on expression of EGFR, HER2, HER3, c-Met, and IGF-1R was analyzed by immunoblotting. Cells
were incubated with control or YB-1 siRNA for 48 hours, and lysates were prepared. B, Levels of YB-1, EGFR, HER2, HER3, c-
Met, and IGF-1R expression were measured by densitometry. C, Effect of YB-1 knockdown on proliferation of five lung cancer
cell lines. Data are expressed as the mean  SD of triplicate experiments.
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and EBC-1. Of the five lines, expression of growth factor
receptors was particularly susceptible to siRNA-dependent
down-regulation in PC-9 and EBC-1 cells, which contain rela-
tively lower levels of YB-1. However, we did not observe
decreased expression of growth factor receptor proteins by YB-1
knockdown in 11_18 and A549 cells (Figures 2A, B). Overall,
the reduced expression of EGFR family proteins and c-Met
protein by YB-1 knockdown in some NSCLC cell lines suggests
an association between YB-1 levels and expression of EGFR
family proteins or c-Met protein. In addition, proliferation of
FIGURE 3. Histologic findings and expression of
YB-1, EGFR, HER2, HER3, c-Met, and pAkt in hu-
man lung cancer. YB-1 expression was assessed as
two patterns: nuclear positive or negative. Cancer
cells showed strong expression of EGFR, HER2,
HER3, and c-Met in the membrane. Moderate-to-
strong expression of pAkt was found in the cyto-
plasm.
TABLE 1. Correlation Between Nuclear YB-1 Expression and Expression of Five Target Genes in
Adenocarcinoma and Squamous Cell Carcinoma of NSCLC
Variables






Negative Positive Negative Positive
n % n % n % n %
EGFR
Negative 42 63.6 30 63.8 12 63.2 1.000 25 65.8 10 76.9 15 60.0 0.473
Positive 24 36.4 17 36.2 7 36.8 13 34.2 3 23.1 10 40.0
HER2
Negative 60 90.9 45 95.7 15 78.9 0.052 36 94.7 11 84.6 25 100.0 0.111
Positive 6 9.1 2 4.3 4 21.1 2 5.3 2 15.4 0 0.0
HER3
Negative 37 56.1 26 55.3 11 57.9 1.000 33 86.8 9 69.2 24 96.0 0.038
Positive 29 43.9 21 44.7 8 42.1 5 13.2 4 30.8 1 4.0
c-Met
Negative 47 71.2 34 72.3 13 68.4 0.770 35 92.1 11 84.6 24 96.0 0.265
Positive 19 28.8 13 27.7 6 31.6 3 7.9 2 15.4 1 4.0
pAkt
Negative 41 62.1 29 61.7 12 63.2 1.000 27 71.1 9 69.2 18 72.0 1.000
Positive 25 37.9 18 38.3 7 36.8 11 28.9 4 30.8 7 28.0
YB-1, Y-box binding protein-1; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor.
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NSCLC cell lines was markedly suppressed to a similar extent in
all five cell types, by 2 to 50 nmol/L of YB-1 siRNA (Figure 2C).
Association of Nuclear YB-1 Expression with
Expression of EGFR, HER2, HER3, c-Met, and
pAkt in NSCLC
To examine which genes are specifically associated
with nuclear YB-1 localization in human NSCLC, we se-
lected five molecular markers: EGFR, HER2, HER3, c-Met,
and pAkt. Representative immunohistochemical staining pat-
terns are shown in Figure 3. Expression of nuclear YB-1 was
detected in 44 of 104 patients. Table 1 shows the results of
Fisher’s exact test for association between YB-1 and each
of the molecular markers in adenocarcinoma and squa-
mous cell carcinoma. To avoid misinterpretations arising
from Simpson’s paradox,22 we emphasis on analysis by
histologic differentiation. Such analysis demonstrated that
there was significant negative correlation between nuclear
expression of YB-1 and expression of HER3 in patients
with squamous cell carcinoma (p  0.038). There was also
a trend to a correlation between nuclear expression of
YB-1 and expression of HER2 in patients with adenocar-
cinoma (p  0.052).
Nuclear YB-1 Expression and Survival of
Patients with NSCLC
The estimated product-limit survival functions of nu-
clear YB-1 are shown in Figure 4, and the results of log-rank
tests and unadjusted HRs are given in Table 2. Survival
curves for patients with positive nuclear YB-1 expression
were significantly different from those with negative expres-
sion (HR  1.73; 95% confidence interval [CI] 1.05–2.83;
p  0.028). Further analysis showed that positive nuclear
YB-1 expression significantly affected survival in adenocar-
cinoma (HR  2.40; 95% CI 1.25–4.58; p  0.007) but not
in squamous cell carcinoma (HR  1.50; 95% CI 0.60–3.72;
p  0.381; Table 2).
Adjusted HRs for patients with positive nuclear YB-1
expression relative to those with negative nuclear YB-1
expression were obtained by applying the Cox regression
models with sex, smoking status, and histologic type as
explanatory variables (Table 3). Stage was not adjusted in
the Cox regression model, because it might be an intermedi-
ate variable between YB-1 expression and overall survival.23
The adjusted HR was statistically significantly different from
unity (HR  1.96; 95% CI 1.13–3.38; p  0.016) indicating
that nuclear YB-1 expression affects overall survival even
after adjusting for possible confounding factors. The Cox
regression models with sex and smoking status were also
applied separately by histologic type to determine the inter-
action between nuclear YB-1 and histologic type. Adjusted
HRs for YB-1 expression were similar between adenocarci-
noma and squamous cell carcinoma, although they were
statistically significant only for patients with adenocarcinoma
(HR  2.19; 95% CI 1.12–4.28; p  0.022 for adenocarci-
noma, and HR  2.14; 95% CI 0.74–6.15; p  0.158 for
squamous cell carcinoma).
Nuclear YB-1 Expression and Therapeutic
Efficacy of Gefitinib
Twenty-six patients administrated gefitinib after pro-
gressive disease. Among 26 patients, 24 patients were histo-
logically diagnosed adenocarcinoma and other two patients
were diagnosed squamous cell carcinoma. Eight of them were
men and 18 were women. Seven of them were smoker and 19
were nonsmoker. The estimated product-limit survival func-
tions of nuclear YB-1 for time to further disease progression
from the initiation of gefitinib treatment are shown in Figure
5. Although patients’ number for gefitinib treatment was
FIGURE 4. Kaplan-Meier plots of overall survival according
to nuclear YB-1 expression in 104 patients with lung cancer.
A, Total patients with NSCLC (n  104), (B) patients with
adenocarcinoma (n  66), and (C) patients with squamous
cell carcinoma (n  38).
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limited, the survival curves for patients with positive nuclear
YB-1 expression and those with negative expression are quite
distinct with statistical significance (p  0.004).
DISCUSSION
Wu et al.18 used array studies to establish a close
correlation between total YB-1 expression and EGFR and
HER2 expression in tumor tissue from patients with breast
cancer. Our recent immunohistochemical analysis demon-
strated that nuclear YB-1 expression is positively correlated
with HER2, and negatively correlated with ER and CXCR4,
but not with EGFR in breast cancer clinical specimens.9 In
this study, YB-1 knockdown in five NSCLC cell lines caused
down-regulation of EGFR, HER2, HER3, and c-Met in PC-9;
of HER3 and c-Met in EBC-1; and of HER3 in QG56. There
was no change in expression of growth factor receptor family
proteins in the other two cell lines. However, cell prolifera-
tion was markedly suppressed by YB-1 knockdown in all five
cell lines suggesting that YB-1 siRNA-induced inhibition of
cell proliferation might not involve attenuation of these
growth factor receptors. The underlying mechanism of YB-1
siRNA-induced growth inhibition in these cell lines remains
TABLE 2. Univariate Analysis of Patients Characteristics and Expression of Nuclear YB-1 and Other Target
Genes in Relation to Regarding Overall Survival
Variables







HR (95% CI) p HR (95% CI) p HR (95% CI) p
YB-1
Negative 47 1.00 0.007 13 1.00 0.381 60 1.00 0.028
Positive 19 2.40 (1.25–4.58) 25 1.50 (0.60–3.72) 44 1.73 (1.05–2.83)
EGFR
Negative 42 1.00 0.098 25 1.00 0.190 67 1.00 0.701
Positive 24 1.71 (0.90–3.23) 13 0.52 (0.19–1.41) 37 1.11 (0.66–1.87)
HER2
Negative 60 1.00 0.566 36 1.00 0.005a 96 1.00 0.130
Positive 6 1.36 (0.48–3.86) 2 6.89 (1.45–32.7) 8 1.91 (0.82–4.47)
HER3
Negative 37 1.00 0.173 33 1.00 0.468 70 1.00 0.155
Positive 29 0.64 (0.33–1.23) 5 0.59 (0.14–2.52) 34 0.66 (0.38–1.17)
c-Met
Negative 47 1.00 0.528 35 1.00 0.645 82 1.00 0.428
Positive 19 1.24 (0.64–2.40) 3 1.41 (0.33–6.12) 22 1.27 (0.71–2.27)
pAkt
Negative 41 1.00 0.540 27 1.00 0.087 68 1.00 0.128
Positive 25 0.82 (0.42–1.57) 11 0.40 (0.13–1.19) 36 0.65 (0.38–1.14)
a Significance of HER2 for squamous cell carcinoma may be artefactual obtained since only 2 patients with HER2 positive were observed and they
happened to have extremely short overall survival by chance.
95% CI, 95% confidence interval; HR, hazard ratio; YB-1, Y-box binding protein-1; EGFR, epidermal growth factor receptor.
TABLE 3. Cox Regression Analysis for Overall Survival
Adenocarcinoma Squamous Cell Carcinoma Total
HR (95% CI) p HR (95% CI) p HR (95% CI) p
YB-1
Negative 1.00 0.022 1.00 0.158 1.00 0.016
Positive 2.19 (1.12–4.28) 2.14 (0.74–6.15) 1.96 (1.13–3.38)
Gender
Negative 1.00 0.218 1.00 0.764 1.00 0.380
Positive 1.77 (0.63–5.03) 0.71 (0.17–3.64) 1.51 (0.61–3.75)
Smoking
Negative 1.00 0.726 1.00 0.414 1.00 0.655




95% CI, 95% confidence interval; HR, hazard ratio; YB-1, Y-box binding protein-1.
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unknown. Immunohistochemical analysis of clinical samples
of NSCLC showed that nuclear YB-1 expression was nega-
tively correlated with HER3 expression in squamous cell
carcinoma (p  0.038) and positively correlated with HER2
expression in adenocarcinoma (p 0.052). However, nuclear
YB-1 expression was not significantly correlated with EGFR
or c-Met expression in either squamous cell carcinoma or
adenocarcinoma.
Overexpression of HER2 in an NSCLC cell line with
very low EGFR and high HER3 expression levels sensitizes
these cells to growth inhibition by the EGFR-targeting drug
gefitinib, and gefitinib abrogated formation of HER2/HER3
heterodimers.24 Consistent with this report, there is a strong
correlation between HER3 expression and sensitivity to ge-
fitinib.25 Another EGFR-targeting drug, erlotinib, also inhib-
its HER2 tyrosine kinase, and HER2/HER3 heterodimer
formation sensitizes lung cancer cells to growth inhibition by
erlotinib.26 Taken together, expression of HER2 and HER3
coupled with formation of their heterodimers plays a critical
role in determining the therapeutic efficacy of the EGFR-
targeting drugs gefitinib and erlotinib.27,28 The possible link
between nuclear YB-1 expression and HER2 expression in
adenocarcinoma (p  0.052) might be in part responsible for
the correlation between nuclear YB-1 expression and survival
of patients with adenocarcinoma NSCLC. Nuclear YB-1
expression is positively correlated with HER2 expression in
patients with breast cancer (p 0.015).9 Thus, HER2 expres-
sion could be modulated by nuclear YB-1 expression not only
in patients with breast cancer9 but also in patients with
adenocarcinoma NSCLC (this study). HER3 expression was
inversely correlated with nuclear expression of YB-1 in
squamous cell carcinoma (p  0.038), but HER3 expression
alone did not correlate with survival of patients with NSCLC
or of the subset with squamous cell carcinoma. It seems
unlikely that the inverse correlation of nuclear YB-1 expres-
sion with HER3 expression is a factor in the poor prognosis
associated with nuclear YB-1 expression in patients with
squamous NSCLC.
In addition to the effect of altering the status of EGFR
family proteins on the therapeutic efficacy of EGFR-targeting
drugs, amplification of c-Met has been identified as another
acquired drug resistance mechanism.29 c-Met modifies drug
sensitivity to gefitinib through HER3-dependent activation of
the PI3K/Akt pathway.25 Moreover, Cappuzzo et al.30 re-
ported that gefitinib-treated patients with a high-HER3 gene
copy number had significantly higher response rates and
times to progression, although with no improvement in over-
all survival. Nuclear expression of YB-1 also affected expres-
sion of c-Met in two NSCLC cell lines in culture, but we
could not observe any significant correlation between nuclear
YB-1 expression and c-Met expression in NSCLC. This
suggests that it is unlikely that nuclear YB-1 expression
determines c-Met expression in patients with NSCLC.
Nuclear YB-1 expression is often associated with poor
prognosis in various human malignancies, including breast can-
cer.4–10 In NSCLC, our previous IHC study on 196 patients
demonstrated that nuclear YB-1 expression is significantly as-
sociated with poor prognosis in all patients (p  0.0424) and in
patients with squamous cell carcinoma (p  0.0313), but not in
patients with adenocarcinoma (p  0.2015).8 This study dem-
onstrated a close association of nuclear YB-1 expression with
poor prognosis in all patients (p  0.028) and in patients with
adenocarcinoma (p 0.007), but not in patients with squamous
cell carcinoma (p 0.381). This inconsistency may result from
the small number of patients with squamous cell carcinoma in
this study. The results of the Cox regression analysis given in
Table 3 provide similar estimates of the HR of nuclear YB-1
expression in adenocarcinoma and squamous cell carcinoma,
although they were not necessarily statistically significant.
Further studies with more definitive clinicopathological char-
acterization of the patients included are required to establish
the types of NSCLC in which nuclear expression of YB-1
predicts poor prognosis.
Of patients with NSCLC (n  104) tested in this study,
we examined whether therapeutic efficacies of gefitinib were
associated with expression levels of nuclear YB-1 expression
when recurrent 26 patients (24 adenocarcinoma and two
squamous cell carcinoma) were treated with gefitinib. Al-
though the number of treated patients was small, the absence
or presence of nuclear YB-1 expression shows a significant
correlation with differences in the survival curves after pro-
gression disease. Concerning EGFR mutations that are highly
susceptible to the therapeutic efficacy of gefitinib, we also
observed statistically significant differences between patients
with mutant EGFR and those with wild-type EGFR (Azuma
et al, unpublished data). Nuclear YB-1 expression might have
a significant predictive value for progression disease in pa-
tients with NSCLC when treated with EGFR-targeting drug.
Further study is in progress whether nuclear expression of
YB- 49 could be associated with gefitinib-susceptible EGFR
mutations.
In conclusion, our results show that nuclear YB-1
expression is strongly associated with overall survival of
patients with NSCLC (n  104). Of the EGFR family
proteins, nuclear YB-1 expression is associated with expres-
sion of HER2 in both histologic types of NSCLC and of
HER3 in squamous cell carcinoma type of NSCLC. There-
fore, expression of YB-1 in the nucleus might affect the
therapeutic efficacy of EGFR-targeting drugs. Nuclear YB-1
FIGURE 5. Kaplan-Meier estimate for time to further pro-
gressive disease from the initiation of gefitinib according to
nuclear YB-1 expression in 26 patients treated with gefitinib
after progressive disease.
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expression is associated with progressive disease survival of
patients with NSCLC (n  26) when treated with gefitinib.
Together, these observations indicate that nuclear YB-1 is a
novel biomarker in NSCLC.
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